Progress in Cardiovascular Diseases
Volume 49, Issue 2 , Pages 123-151, September 2006

Pathophysiology and Treatment of Hypertrophic Cardiomyopathy

  • Mark V. Sherrid

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mark V. Sherrid, MD, 1000 10th Avenue 3B-30, New York City, NY 10019.

Hypertrophic Cardiomyopathy Program and Echocardiography Laboratory, Department of Medicine, Division of Cardiology, St. Luke's-Roosevelt Hospital Center, College of Physicians and Surgeons, Columbia University, New York, NY

All patients with hypertrophic cardiomyopathy (HCM) should have five aspects of care addressed. An attempt should be made to detect the presence or absence of risk factors for sudden arrhythmic death. If the patient appears to be at high risk, discussion of the benefits and risks of ICD are indicated, and many such patients will be implanted. Symptoms are appraised and treated. Bacterial endocarditis prophylaxis is recommended. Patients are advised to avoid athletic competition and extremes of physical exertion. First degree family members should be screened with echocardiography and ECG.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0033-0620(06)00085-5

doi:10.1016/j.pcad.2006.08.001

Progress in Cardiovascular Diseases
Volume 49, Issue 2 , Pages 123-151, September 2006